TOKYO -- Japanese vaccine makers are racing to release COVID vaccines next year as they anticipate new virus variants and further outbreaks.
KM Biologics, a Meiji Holdings subsidiary, said on Wednesday that it is aiming for the release of its inactivated vaccine for use as booster shots next year. The Kumamoto-based company began a Phase 2/3 trial last week.
